Amgen Sets Up For Independence In Korea
This article was originally published in PharmAsia News
In a sign South Korea is becoming an increasingly important market for multinational biopharma firms, Amgen has set up an independent affiliate in the country. The US biotech giant plans to bring more clinical trials and innovative therapies for serious diseases to a country that it sees as offering medical excellence and a large and diverse patient population.
You may also be interested in...
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.